

Samantha Alvarez-Madrazo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8151509/publications.pdf>

Version: 2024-02-01

11
papers

448
citations

1040056

9
h-index

1281871

11
g-index

12
all docs

12
docs citations

12
times ranked

871
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 653-663.	1.9	9
2	Discontinuation, persistence and adherence to subcutaneous biologics delivered via a homecare route to Scottish adults with rheumatic diseases: a retrospective study. <i>BMJ Open</i> , 2019, 9, e027059.	1.9	10
3	Bleeding in cardiac patients prescribed antithrombotic drugs: electronic health record phenotyping algorithms, incidence, trends and prognosis. <i>BMC Medicine</i> , 2019, 17, 206.	5.5	12
4	Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 422-431.	2.4	43
5	Use of text-mining methods to improve efficiency in the calculation of drug exposure to support pharmacoepidemiology studies. <i>International Journal of Epidemiology</i> , 2018, 47, 617-624.	1.9	23
6	Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine. <i>Expert Review of Vaccines</i> , 2018, 17, 1123-1133.	4.4	16
7	Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1378-1386.	1.9	31
8	Data Resource Profile: The Scottish National Prescribing Information System (PIS). <i>International Journal of Epidemiology</i> , 2016, 45, 714-715f.	1.9	104
9	Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. <i>Frontiers in Pharmacology</i> , 2014, 5, 109.	3.5	44
10	Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. <i>Frontiers in Pharmacology</i> , 2014, 5, 106.	3.5	107
11	Different initiatives across Europe to enhance losartan utilization post generics: impact and implications. <i>Frontiers in Pharmacology</i> , 2014, 5, 219.	3.5	48